Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigen, Bionomics Expand Target-Discovery Collaboration

NEW YORK, Jan. 30 - Hybrigen and Bionomics have expanded their drug target-discovery relationship to include a new angiogenesis target discovered by Bionomics, the companies said on Wednesday.


They also announced plans jointly to launch a new enterprise to commercialize discoveries made in the collaboration.


The two companies inked a target discovery partnership last September to study two genes linked to breast cancer. Bionomics had identified and patented the genetic data, and Hybrigen brought its proteomic expertise to discover relevant drug targets. The two companies share rights to any drug targets developed in that collaboration.


The relationship will now include Bionomics' angiogenesis genes to which it has rights. Again, both companies will co-own the drug targets.


Bionomics, based in Adelaide, Australia, focuses on discovering and characterizing disease-related genes, especially in breast cancer, epilepsy, and angiogenesis.


Hybrigen is headquartered in Dallas, Tex. It has developed a proteomic platform to assist in drug target-discovery and characterization.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.